Cássia Emanuella Nóbrega Malta1, Anna Clara Aragão Matos Carlos2, Manuele Carine Maciel de Alencar3, Eveline Fernandes Alves E Silva3, Victor Bruno Caitano Nogueira3, Ana Paula Negreiros Nunes Alves1, Fábio Figueiredo Chaves3, José Fernando Bastos de Moura3, Paulo Goberlânio de Barros Silva4,5,6. 1. Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Rua Monsenhor Furtado, S/N - Rodolfo Teófilo, Fortaleza, Ceará, 60430-355, Brazil. 2. Department of Dentistry, Unichristus, Fortaleza, Ceará, Brazil. 3. Ceará Oncology School, Ceará Cancer Institute, Hospital Haroldo Juaçaba, Fortaleza, Ceará, Brazil. 4. Department of Dental Clinic, Division of Oral Pathology, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Rua Monsenhor Furtado, S/N - Rodolfo Teófilo, Fortaleza, Ceará, 60430-355, Brazil. paulo_goberlanio@yahoo.com.br. 5. Department of Dentistry, Unichristus, Fortaleza, Ceará, Brazil. paulo_goberlanio@yahoo.com.br. 6. Ceará Oncology School, Ceará Cancer Institute, Hospital Haroldo Juaçaba, Fortaleza, Ceará, Brazil. paulo_goberlanio@yahoo.com.br.
Abstract
PURPOSE: To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). METHODS: This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of four cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher's exact tests. RESULTS: PBMT patients showed less objective and subjective taste loss (p<0.05). On the other hand, the placebo group showed a higher ECOG status (p=0.037) and more significant weight loss (p<0.001) after four cycles of AC. The QoL was significantly higher in the PBMT group (p<0.05) at all assessment periods, and PBMT treatment also reduced the incidence of cachexia (p=0.020), anorexia (p<0.001), diarrhea (p=0.040), oral mucositis (p=0.020), and vomiting (p=0.008). CONCLUSION: PBMT reduced the taste loss and improved the overall health status and QoL of patients with breast cancer treated with AC. TRIAL REGISTRATION: Brazilian Clinical Trials Registry ( www.ensaiosclinicos.gov.br ) approval number RBR-9qnm34y, registered on 01/05/2021.
PURPOSE: To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). METHODS: This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of four cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher's exact tests. RESULTS: PBMT patients showed less objective and subjective taste loss (p<0.05). On the other hand, the placebo group showed a higher ECOG status (p=0.037) and more significant weight loss (p<0.001) after four cycles of AC. The QoL was significantly higher in the PBMT group (p<0.05) at all assessment periods, and PBMT treatment also reduced the incidence of cachexia (p=0.020), anorexia (p<0.001), diarrhea (p=0.040), oral mucositis (p=0.020), and vomiting (p=0.008). CONCLUSION: PBMT reduced the taste loss and improved the overall health status and QoL of patients with breast cancer treated with AC. TRIAL REGISTRATION: Brazilian Clinical Trials Registry ( www.ensaiosclinicos.gov.br ) approval number RBR-9qnm34y, registered on 01/05/2021.
Authors: Jae Hee Hong; Pinar Omur-Ozbek; Brian T Stanek; Andrea M Dietrich; Susan E Duncan; Yong Woo Lee; Glenn Lesser Journal: J Support Oncol Date: 2009 Mar-Apr
Authors: Y C de Vries; M M G A van den Berg; J H M de Vries; S Boesveldt; J Th C M de Kruif; N Buist; A Haringhuizen; M Los; D W Sommeijer; J H N Timmer-Bonte; H W M van Laarhoven; M Visser; E Kampman; R M Winkels Journal: Support Care Cancer Date: 2017-03-16 Impact factor: 3.603
Authors: Y C de Vries; S Boesveldt; C S Kelfkens; E E Posthuma; M M G A van den Berg; J Th C M de Kruif; A Haringhuizen; D W Sommeijer; N Buist; S Grosfeld; C de Graaf; H W M van Laarhoven; E Kampman; R M Winkels Journal: Breast Cancer Res Treat Date: 2018-02-23 Impact factor: 4.872